A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo

Oncotarget

Volumn 5, Issue 11, 2014, Pages 3836-3848

  Tang, Juan ^a   Zhu, Jingyu ^a   Yu, Yang ^a   Zhang, Zubin ^a   Chen, Guodong ^a   Zhou, Xiumin ^b   Qiao, Chunhua ^a   Hou, Tingjun ^a,c   Mao, Xinliang ^a,d  

^a SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d Key Laboratory of Thrombosis and Hemostasis of National Health Commission   (China)

Author keywords

Apoptosis; C96; Multiple myeloma; PI3K AKT signal pathway; Virtual screen

Indexed keywords

AKT1 PROTEIN; AKT3 PROTEIN; C 96; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN TYROSINE KINASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; FEMALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL GROWTH; DRUG EFFECTS; ENZYMOLOGY; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; MULTIPLE MYELOMA; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903542968     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1657     Document Type: Article

References (37)

1. Kyle RA and Rajkumar SV. Multiple myeloma. Blood. 2008; 111(6):2962-2972.
2. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR and Larson DR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78(1):21-33.
3. Cao B, Li J and Mao X. Dissecting bortezomib: development, application, adverse effects and future direction. Curr Pharm Des. 2013; 19(18):3190-3200.
4. Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD, Habtemariam B, Bullock J, Bray JD and Hawes J. U.s. Food and drug administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res. 2013; 19(17):4559-4563.
5. Li J, Cao B, Zhou S, Zhu J, Zhang Z, Hou T and Mao X. Cyproheptadine-induced myeloma cell apoptosis is associated with inhibition of the PI3K/AKT signaling. Eur J Haematol. 2013.
6. Mao X, Cao B, Wood TE, Hurren R, Tong J, Wang X, Wang W, Li J, Jin Y and Sun W. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood. 2011; 117(6):1986-1997.
7. So L and Fruman DA. PI3K signalling in B-and T-lymphocytes: new developments and therapeutic advances. Biochem J. 2012; 442(3):465-481.
8. Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L and Vallet S. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010; 116(9):1460-1468.
9. Glauer J, Pletz N, Schon M, Schneider P, Liu N, Ziegelbauer K, Emmert S, Wulf GG and Schon MP. A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo. Blood Cancer J. 2013; :3:e141.
10. Chiron D, Maiga S, Surget S, Descamps G, Gomez-Bougie P, Traore S, Robillard N, Moreau P, Le Gouill S and Bataille R. Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells. Blood Cancer J. 2013; :3:e120.
11. Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M and Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012; 120(18):3783-3792.
12. Billottet C, Banerjee L, Vanhaesebroeck B and Khwaja A. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res. 2009; 69(3):1027-1036.
13. Gan F, Cao B, Wu D, Chen Z, Hou T and Mao X. Exploring old drugs for the treatment of hematological malignancies. Curr Med Chem. 2011; 18(10):1509-1514.
14. Frederick R, Mawson C, Kendall JD, Chaussade C, Rewcastle GW, Shepherd PR and Denny WA. Phosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screening. Bioorg Med Chem Lett. 2009; 19(20):5842-5847.
15. Castillo JJ, Iyengar M, Kuritzky B and Bishop KD. Isotypespecific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies. Onco Targets Ther. 2014; 7:333-342.
16. Walker EH, Perisic O, Ried C, Stephens L and Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature. 1999; 402(6759):313-320.
17. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A and Toth B. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006; 125(4):733-747.
18. Liu P, Cheng H, Roberts TM and Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-644.
19. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D and Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006; 94(2): 195-199.
20. Han K, Xu X, Chen G, Zeng Y, Zhu J, Du X, Zhang Z, Cao B, Liu Z and Mao X. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization. J Hematol Oncol. 2014; 7(1):9.
21. Harvey RD and Lonial S. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol. 2007; 3(6):639-647.
22. Li J, Zhu J, Cao B and Mao X. The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma. Curr Pharm Des. 2014; 20:125-35.
23. Lee G, Ramirez CN, Kim H, Zeltner N, Liu B, Radu C, Bhinder B, Kim YJ, Choi IY and Mukherjee-Clavin B. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol. 2012; 30(12): 1244-1248.
24. Mao X, Stewart AK, Hurren R, Datti A, Zhu X, Zhu Y, Shi C, Lee K, Tiedemann R and Eberhard Y. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood. 2007; 110(12): 4047-4054.
25. Link W, Oyarzabal J, Serelde BG, Albarran MI, Rabal O, Cebria A, Alfonso P, Fominaya J, Renner O and Peregrina S. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem. 2009; 284(41): 28392-28400.
26. Pinson JA, Schmidt-Kittler O, Zhu J, Jennings IG, Kinzler KW, Vogelstein B, Chalmers DK and Thompson PE. Thiazolidinedione-based PI3Kalpha inhibitors: an analysis of biochemical and virtual screening methods. ChemMed Chem. 2011; 6(3):514-522.
27. Park H, Lee S and Hong S. Discovery of MEK/PI3K dual inhibitor via structure-based virtual screening. Bioorg Med Chem Lett. 2012; 22(15):4946-4950.
28. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM and Knight ZA. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008; 4(11):691-699.
29. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005; 4(12):988-1004.
30. Zhu J, Pan P, Li Y, Wang M, Li D, Cao B, Mao X and Hou T. Theoretical studies on beta and delta isoformspecific binding mechanisms of phosphoinositide 3-kinase inhibitors. Mol Biosyst. 2014; 10(3):454-66.
31. Venable JD, Ameriks MK, Blevitt JM, Thurmond RL and Fung-Leung WP. Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease. Recent Pat Inflamm Allergy Drug Discov. 2014; 4(1):1-15.
32. Fukushima T, Nakamura Y, Yamanaka D, Shibano T, Chida K, Minami S, Asano T, Hakuno F and Takahashi S. Phosphatidylinositol 3-kinase (PI3K) activity bound to insulin-like growth factor-I (IGF-I) receptor, which is continuously sustained by IGF-I stimulation, is required for IGF-I-induced cell proliferation. J Biol Chem. 2012; 287(35):29713-29721.
33. Pennarun B, Kleibeuker JH, Oenema T, Stegehuis JH, de Vries EG and de Jong S. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL. Cell Oncol (Dordr). 2011; 34(3):245-259.
34. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB and Younes A. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol. 2006; 132(4): 503-511.
35. Ohwada J, Ebiike H, Kawada H, Tsukazaki M, Nakamura M, Miyazaki T, Morikami K, Yoshinari K, Yoshida M and Kondoh O. Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. Bioorg Med Chem Lett. 2011; 21(6):1767-1772.
36. Ling C, Chen G, Chen G, Zhang Z, Cao B, Han K, Yin J, Chu A, Zhao Y and Mao X. A deuterated analog of dasatinib disrupts cell cycle progression and displays antinon-small cell lung cancer activity in vitro and in vivo. Int J Cancer. 2012; 131(10):2411-2419.
37. Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley L, Hideshima T and Munshi NC. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. 2003; 101(7):2762-2769.